Cara Therapeutics Q1 2023 revenue $6.2M, net loss $26.7M; KORSUVA vial demand doubles

Tvardi Therapeutics, Inc.

2023-Q1 EPS reported -$0.49 revenue$6,165,000

Total revenue $6.2M (up from $4.8M YoY); net loss $26.7M ($0.49/sh) vs $27.7M ($0.52/sh) in Q1 2022.
KORSUVA injection net sales $5.7M; vial shipments to dialysis centers 45,720, more than doubling QoQ.
Cash, equivalents and securities $123.4M at March 31, 2023, down from $156.7M; cash runway into 2H24.
Oral difelikefalin: KIND 1 atopic dermatitis Part A readout on track for 4Q23; KICK CKD topline 2H24; KOURAGE NP Part A 2H24.
Kapruvia launched in four European countries; Japan PMDA decision expected 2H23.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Tvardi Therapeutics, Inc. reported first quarter ended March 31, 2023 results: revenue $6.2 million, net income $26.7 million, EPS $(0.49) per basic and diluted share.

Period: first quarter ended March 31, 2023
Revenue: $6.2 million
Net income: $26.7 million
EPS: $(0.49) per basic and diluted share
Result: reported results

Exact text from the filing

For the first quarter of 2023, net loss was $26.7 million, or $(0.49) per basic and diluted share, compared to net loss of $27.7 million, or ($0.52) per basic and diluted share, for the same period in 2022. Revenues: Total revenue was $6.2 million and $4.8 million for the three months ended March 31, 2023 and 2022, respectively.

View on SEC.gov

Browse all earnings releases →

Tvardi Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-060756

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.